NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

Table 9 AVIATOR, phase IIa study (combination of ABT-450 + ritonavir + ABT-333 + ribavirin)

Study arm	n	Genotype	Status	Combination	Duration	Treatment regimen	SVR
Total: group 1 + 2	33	1а/1b (28/5)	Naive	АВТ-450 + ritonavir + АВТ-333 + ribavirin	12 wk	АВТ-450, 250 mg/d or 150 mg/d + ritonavir, 100 mg/d; АВТ-333, 400 mg BID; ribavirin, body weight-based	93%-95%
3	17	1а/1b (16/1)	partial virologic response, null response	АВТ-450 + ritonavir + АВТ-333 + ribavirin	12 wk	АВТ-450, 150 mg/d; ritonavir, 100 mg/d; АВТ-333, 400 mg BID; ribavirin, body weight-based	47%